ORGANOVO HOLDINGS INC (ONVO)
US68620A2033 - Common Stock
Curious about the stocks that are showing activity after the closing bell on Thursday?
Which stocks are moving after the closing bell on Thursday?
Stay updated with the stocks that are on the move in today's after-hours session.
Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting
SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel...
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel...
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
Organovo presented on the Company’s near and long-term outlook, operational plans, at the Jones Trading Healthcare Conference in Encinitas, CA. ...
ONVO Stock Earnings: Organovo Holdings Beats EPS, Misses Revenue for Q4 2024
ONVO stock results show that Organovo Holdings beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024.
ONVO Stock Earnings: Organovo Holdings Beats EPS, Misses Revenue for Q4 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Organovo Holdings (NASDAQ:ONVO) just reported results for the fourth quarter of...
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
Poster presented at DDW2024 demonstrating the potential of the Company’s clinical-stage compound, FXR314, in combination with tofacitinib for treating...
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
Renowned gastrointestinal diseases conference to held in Washington, D.C. May 18-21, 2024
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
Organovo will be presenting data on the Company’s lead clinical-stage drug, FXR314 during DDW2024, which is being held in Washington, D.C. May 18-21, 2024...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a hot topic this morning and we've got traders covered with all of the news behind these movements on Thursday!
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
ONVO announced the pricing of a public offering consisting of 6,562,500 shares of common stock (or pre-funded warrants in lieu thereof)....
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat...
Organovo files for $150M mixed shelf (NASDAQ:ONVO)
Organovo (NASDAQ:ONVO) disclosed in an SEC filing on Friday a prospectus to offer and sell common stock, preferred stock, debt securities, warrants, units...
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing FXR314...
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
SAN DIEGO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing...
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing...
CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 8, 2023 by Organovo, Inc. (NASDAQ: ONVO), a link was...
Organovo Highlights FXR314 Combination Therapy Potential and Plan
Organovo Highlights FXR314 Combination Therapy Potential and Plan
SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing...